{
    "id": 23963,
    "fullName": "SELE positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "SELE positive indicates the presence of the SELE gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 6401,
        "geneSymbol": "SELE",
        "terms": [
            "SELE",
            "CD62E",
            "ELAM",
            "ELAM1",
            "ESEL",
            "LECAM2"
        ]
    },
    "variant": "positive",
    "createDate": "06/30/2016",
    "updateDate": "01/24/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 7185,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Uproleselan (GMI-1271) inhibited metastasis of breast cancer cells expressing E-selectin ligands in xenograft models (Cancer Res 2014;74(19 Suppl):Abstract nr 4039).",
            "molecularProfile": {
                "id": 24685,
                "profileName": "SELE positive"
            },
            "therapy": {
                "id": 4402,
                "therapyName": "Uproleselan",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6171,
                    "pubMedId": null,
                    "title": "Exploration of a potent E-Selectin antagonist (GMI-1271) as a potential novel therapeutic for treating breast cancer metastasis to the bone and lung",
                    "url": "http://cancerres.aacrjournals.org/content/74/19_Supplement/4039.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7183,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Uproleselan (GMI-1271) reduced chemo-resistance in patient-derived acute myeloid leukemia cells expressing E-selectin ligands in culture, and decreased tumor burden in xenograft models (Blood 126(21):61).",
            "molecularProfile": {
                "id": 24685,
                "profileName": "SELE positive"
            },
            "therapy": {
                "id": 4402,
                "therapyName": "Uproleselan",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6169,
                    "pubMedId": null,
                    "title": "Adhesion Of Acute Myeloid Leukemia Blasts To E-Selectin In The Vascular Niche Enhances Their Survival By Mechanisms Such As Wnt Activation",
                    "url": "http://www.bloodjournal.org/content/122/21/61.short?sso-checked=true"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15759,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II trial, Uproleselan (GMI-1271) in combination with chemotherapy (mitoxantrone, etoposide, and cytarabine) demonstrated safety and efficacy, resulted in a CR/CRi rate of 39% (26/66) in patients with relapsed/refractory acute myeloid leukemia (R/R AML), and 72% (18/25) in treatment-naive patients, with improved remission and survival associated with high E-selectin expression in R/R AML patients (ASH Annual Meeting, Dec 2018, Abstract 331).",
            "molecularProfile": {
                "id": 24685,
                "profileName": "SELE positive"
            },
            "therapy": {
                "id": 4402,
                "therapyName": "Uproleselan",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13766,
                    "pubMedId": null,
                    "title": "Uproleselan (GMI-1271), an E-Selectin Antagonist, Improves the Efficacy and Safety of Chemotherapy in Relapsed/Refractory (R/R) and Newly Diagnosed Older Patients with Acute Myeloid Leukemia: Final, Correlative and Subgroup Analyses",
                    "url": "https://ash.confex.com/ash/2018/webprogram/Paper114286.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 24685,
            "profileName": "SELE positive",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}